BARD1 Life Sciences Ltd (ASX:BD1) (BARD1 or the Company) is a leading Australian diagnostics company with an innovative portfolio of diagnostic technologies and products. The Company is focused on developing and commercialising diagnostic solutions for healthcare professionals and patients. BARD1 has commercialised the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET® pan-exosome capture tool for research purposes. Our cancer diagnostic pipeline includes tests in development for ovarian and breast cancers, and research-stage projects for prostate and pancreatic cancers.

4 November 2021
BARD1 Life Sciences (ASX:BD1) Presentation, Online Investor Event


“The Company’s technologies include the BARD1 biomarker technology, hTERT ICC assay, SIEN-NET biomarker capture platform and Sub-B2M pan-cancer probe creating a powerful growth engine to develop in-house and partnered diagnostic and therapeutic products with the potential to generate sustainable product and licensing revenues”


“The Company has a cancer diagnostics portfolio of marketed and development-stage products for multiple cancer indications”